Lifeward (LFWD) Registration Filing summary

Company overview and business model

• Designs, develops, and commercializes medical devices for physical rehabilitation and recovery, serving both clinical and home settings.

• Core products include robotic exoskeletons for spinal cord injury (SCI), with FDA-cleared stair and curb functionality and a next-generation model pending FDA review.

• Expanded offerings through acquisition of AlterG, a provider of Anti-Gravity systems, and distribution agreements for rehabilitation devices.

• Principal markets are the U.S. and Europe, with sales through direct channels and distributors; recent focus on workers' compensation market via exclusive distribution agreement.

• Research on new products like ReBoot exo-suit is ongoing but currently paused pending further evaluation.

Financial performance and metrics

• Incorporates by reference annual and quarterly SEC filings, including the 2024 Annual Report and 2025 quarterly reports, for detailed financial data.

• Recent acquisition of AlterG involved a $19 million cash payment and potential earnouts based on revenue growth.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes unless otherwise specified in a prospectus supplement.